Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation DOI

Rushikesh K Patil,

Vaibhavi Srivastava, Rohit Bhawale

и другие.

Nanomedicine, Год журнала: 2024, Номер 19(11), С. 947 - 964

Опубликована: Март 14, 2024

Aim: This study aims to explore potential of transniosomes, a hybrid vesicular system, as ocular drug-delivery vehicle. Materials & methods: Thin-film hydration technique was used fabricate brinzolamide-loaded transniosomes (BRZ-TN) and optimized using Box–Behnken design, further exhaustively characterized for physicochemical evaluations, deformability, drug release, permeation preclinical evaluations antiglaucoma activity. Results: The BRZ-TN showed ultradeformability (deformability index: 5.71), exhibiting sustained release without irritation (irritancy score: 0) high permeability compared with the marketed formulation or free suspension. extensive in vivo investigations affirmed effective targeted delivery brinzolamide reducing intraocular pressure potentially. Conclusion: Our findings anticipated that is promising therapeutic nanocarrier effectively delivering cargo sites by crossing corneal barriers.

Язык: Английский

Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation DOI

Rushikesh K Patil,

Vaibhavi Srivastava, Rohit Bhawale

и другие.

Nanomedicine, Год журнала: 2024, Номер 19(11), С. 947 - 964

Опубликована: Март 14, 2024

Aim: This study aims to explore potential of transniosomes, a hybrid vesicular system, as ocular drug-delivery vehicle. Materials & methods: Thin-film hydration technique was used fabricate brinzolamide-loaded transniosomes (BRZ-TN) and optimized using Box–Behnken design, further exhaustively characterized for physicochemical evaluations, deformability, drug release, permeation preclinical evaluations antiglaucoma activity. Results: The BRZ-TN showed ultradeformability (deformability index: 5.71), exhibiting sustained release without irritation (irritancy score: 0) high permeability compared with the marketed formulation or free suspension. extensive in vivo investigations affirmed effective targeted delivery brinzolamide reducing intraocular pressure potentially. Conclusion: Our findings anticipated that is promising therapeutic nanocarrier effectively delivering cargo sites by crossing corneal barriers.

Язык: Английский

Процитировано

0